Market Research Logo

Multiplex Biomarker Imaging Market: North America Expected to be the Most Attractive Regional Market During the Forecast Period: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Multiplex Biomarker Imaging Market: North America Expected to be the Most Attractive Regional Market During the Forecast Period: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Introduction

Future Market Insights presents yet another comprehensive and an insightful report titled ‘Multiplex Biomarker Imaging Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027’. In this report, multiplex biomarker imaging is defined as a unique technique for imaging the characteristics and analysis of exact disease. Biomarkers are in the form of biological markers used in clinical studies to picture the current state of the disease.

Report Structure

This report is divided into four distinct parts to offer clarity and easy readability to the report audiences. The first section of the report is the introduction, which contains the executive summary of the report, the market taxonomy and the definition of the product, namely, multiplex biomarker imaging, by product type and the market viewpoint. The global multiplex biomarker imaging market opportunity analysis is also given in the introduction section. In another subsection of the introduction part, the rules and regulations applying to the multiplex biomarker imaging market from different regions of the world are given. The pricing analysis of the multiplex biomarker imaging market is also given in the introduction section. The second part of the report contains the regional multiplex biomarker imaging market analysis and the regions are chosen as per the market taxonomy. This section contains a valuable subsection which explains the market dynamics of each region of the multiplex biomarker imaging market. These market dynamics are in the form of drivers and restrains and give information about the factors that are responsible for the growth of the multiplex biomarker imaging market and the factors that are responsible for restraining the multiplex biomarker imaging market. The last part of the report contains the global multiplex biomarker imaging market analysis and forecast by region, by component type, by imaging technique, by application and by end user. This section of the report contains important market numbers in the form of market attractiveness index, incremental dollar opportunity and basis point share analysis.

Competition Landscape

Another part of this report contains the competition landscape that contains information about the key players operating in the global multiplex biomarker imaging market. The competition landscape contains a dashboard view of the companies and also have the detailed information for each of the leading individual companies operating in the global multiplex biomarker imaging market. This information is in the form of company description, product overview, key developments, strategic overview and key financials of each of the individual companies. In addition, a SWOT analysis of each of the companies profiled is also given which gives the report audiences information about the strengths, weaknesses, opportunities and the threats that the leading companies operating in the global multiplex biomarker imaging market are facing. This competition landscape is a valuable part of the report as it contains all the necessary information to study the leading companies operating in the global multiplex biomarker imaging market in detail and find how they implement their strategies and vision to stay at top in this highly competitive market. This type of information is invaluable for the new entrants in the global multiplex biomarker imaging market as they can learn quite a bit from the leading companies operating in this market. Also, the information provided in the competition landscape is also valuable for the established companies in the global multiplex biomarker imaging market as they come to know about their competitors and the strategies they have adopted to stay at the pole position in this cut- throat market.

Research Methodology

Overall market size has been analysed through historical data, primary responses, and public domain data. Revenue of companies in the multiplex biomarker imaging market has been benchmarked to ascertain the market size for the base year. Macroeconomic indicators such as GDP and industry growth have been considered to forecast the market size over the forecast period. The historical growth trend of end-use industries, market participants’ performance, as well as the present macro-economic outlook has been taken into consideration for estimating the overall market trend forecast. This data is then validated using the triangulation method and is extensively scrutinised using advanced tools to garner quantitative and qualitative insights into the global multiplex biomarker imaging market.

Market Taxonomy

Component Type

Imaging Technique

Application

End-User

Region

Instruments

Quantitative Pathology

Imaging System

Immunofluorescence Slide Scanner

Toponome imaging System

Multispectral Imaging

Systems

Software

Services

Installation & Integration

Services

Maintenance Service

Immunohistochemistry (IHC) Assay

Fluorescent In Situ

Hybridization (FISH) Assay

Tissue Microarray (TMA) Assay

Research

Clinical Diagnostics

Translation Laboratories

Biopharmaceutical Companies

Academic Institutes

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding

Japan (APEJ)

Japan

Middle East and Africa


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
3.3. Regulatory Scenario
4. North America Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Trends
4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
4.3.1. U.S.
4.3.2. Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
4.4.1. U.S.
4.4.2. Canada
4.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
4.5.1. Instruments
4.5.1.1. Quantitative Pathology Imaging System
4.5.1.2. Immunofluorescence Slide Scanner
4.5.1.3. Multispectral Imaging Systems
4.5.1.4. Toponome imaging System
4.5.2. Software
4.5.3. Services
4.5.3.1. Installation & Integration Services
4.5.3.2. Maintenance Service
4.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
4.6.1. Instruments
4.6.1.1. Quantitative Pathology Imaging System
4.6.1.2. Immunofluorescence Slide Scanner
4.6.1.3. Multispectral Imaging Systems
4.6.1.4. Toponome imaging System
4.6.2. Software
4.6.3. Services
4.6.3.1. Installation & Integration Services
4.6.3.2. Maintenance Service
4.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
4.7.1. Immunohistochemistry (IHC) Assay
4.7.2. Fluorescent In Situ Hybridization (FISH) Assay
4.7.3. Tissue Microarray (TMA) Assay
4.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
4.8.1. Immunohistochemistry (IHC) Assay
4.8.2. Fluorescent In Situ Hybridization (FISH) Assay
4.8.3. Tissue Microarray (TMA) Assay
4.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
4.9.1. Research
4.9.2. Clinical Diagnostics
4.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
4.10.1. Research
4.10.2. Clinical Diagnostics
4.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
4.11.1. Translational Laboratories
4.11.2. Biopharmaceutical Companies
4.11.3. Academic Institutes
4.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
4.12.1. Translational Laboratories
4.12.2. Biopharmaceutical Companies
4.12.3. Academic Institutes
4.13.Drivers and Restraints: Impact Analysis
4.14. Market Attractiveness Analysis
4.14.1. By Country
4.14.2. By Component Type
4.14.3. By Imaging Technique
4.14.4. Application
4.14.5. End User
4.15. Key Representative Market Presence (Intensity Map)
5. Latin America Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Trends
5.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
5.3.1. Brazil
5.3.2. Mexico
5.3.3. Argentina
5.3.4. Rest of Latin America
5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Argentina
5.4.4. Rest of Latin America
5.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
5.5.1. Instruments
5.5.1.1. Quantitative Pathology Imaging System
5.5.1.2. Immunofluorescence Slide Scanner
5.5.1.3. Multispectral Imaging Systems
5.5.1.4. Toponome imaging System
5.5.2. Software
5.5.3. Services
5.5.3.1. Installation & Integration Services
5.5.3.2. Maintenance Service
5.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
5.6.1. Instruments
5.6.1.1. Quantitative Pathology Imaging System
5.6.1.2. Immunofluorescence Slide Scanner
5.6.1.3. Multispectral Imaging Systems
5.6.1.4. Toponome imaging System
5.6.2. Software
5.6.3. Services
5.6.3.1. Installation & Integration Services
5.6.3.2. Maintenance Service
5.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
5.7.1. Immunohistochemistry (IHC) Assay
5.7.2. Fluorescent In Situ Hybridization (FISH) Assay
5.7.3. Tissue Microarray (TMA) Assay
5.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
5.8.1. Immunohistochemistry (IHC) Assay
5.8.2. Fluorescent In Situ Hybridization (FISH) Assay
5.8.3. Tissue Microarray (TMA) Assay
5.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
5.9.1. Research
5.9.2. Clinical Diagnostics
5.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
5.10.1. Research
5.10.2. Clinical Diagnostics
5.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
5.11.1. Translational Laboratories
5.11.2. Biopharmaceutical Companies
5.11.3. Academic Institutes
5.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
5.12.1. Translational Laboratories
5.12.2. Biopharmaceutical Companies
5.12.3. Academic Institutes
5.13.Drivers and Restraints: Impact Analysis
5.14. Market Attractiveness Analysis
5.14.1. By Country
5.14.2. By Component Type
5.14.3. By Imaging Technique
5.14.4. Application
5.14.5. End User
5.15. Key Representative Market Presence (Intensity Map)
6. Western Europe Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1. Drivers
6.2.2. Restraints
6.2.3. Trends
6.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
6.3.1. U.K.
6.3.2. Germany
6.3.3. France
6.3.4. Italy
6.3.5. Spain
6.3.6. Nordics
6.3.7. BENELUX
6.3.8. Rest of Western Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
6.4.1. U.K.
6.4.2. Germany
6.4.3. France
6.4.4. Italy
6.4.5. Spain
6.4.6. Nordics
6.4.7. BENELUX
6.4.8. Rest of Western Europe
6.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
6.5.1. Instruments
6.5.1.1. Quantitative Pathology Imaging System
6.5.1.2. Immunofluorescence Slide Scanner
6.5.1.3. Multispectral Imaging Systems
6.5.1.4. Toponome imaging System
6.5.2. Software
6.5.3. Services
6.5.3.1. Installation & Integration Services
6.5.3.2. Maintenance Service
6.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
6.6.1. Instruments
6.6.1.1. Quantitative Pathology Imaging System
6.6.1.2. Immunofluorescence Slide Scanner
6.6.1.3. Multispectral Imaging Systems
6.6.1.4. Toponome imaging System
6.6.2. Software
6.6.3. Services
6.6.3.1. Installation & Integration Services
6.6.3.2. Maintenance Service
6.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
6.7.1. Immunohistochemistry (IHC) Assay
6.7.2. Fluorescent In Situ Hybridization (FISH) Assay
6.7.3. Tissue Microarray (TMA) Assay
6.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
6.8.1. Immunohistochemistry (IHC) Assay
6.8.2. Fluorescent In Situ Hybridization (FISH) Assay
6.8.3. Tissue Microarray (TMA) Assay
6.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
6.9.1. Research
6.9.2. Clinical Diagnostics
6.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
6.10.1. Research
6.10.2. Clinical Diagnostics
6.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
6.11.1. Translational Laboratories
6.11.2. Biopharmaceutical Companies
6.11.3. Academic Institutes
6.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
6.12.1. Translational Laboratories
6.12.2. Biopharmaceutical Companies
6.12.3. Academic Institutes
6.13.Drivers and Restraints: Impact Analysis
6.14. Market Attractiveness Analysis
6.14.1. By Country
6.14.2. By Component Type
6.14.3. By Imaging Technique
6.14.4. Application
6.14.5. End User
6.15. Key Representative Market Presence (Intensity Map)
7. Eastern Europe Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
7.2.1. Russia
7.2.2. Poland
7.2.3. Rest of Eastern Europe
7.3. Market Size (US$ Mn) Forecast By Country,2017-2027
7.3.1. Russia
7.3.2. Poland
7.3.3. Rest of Eastern Europe
7.4. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
7.4.1. Instruments
7.4.1.1. Quantitative Pathology Imaging System
7.4.1.2. Immunofluorescence Slide Scanner
7.4.1.3. Multispectral Imaging Systems
7.4.1.4. Toponome imaging System
7.4.2. Software
7.4.3. Services
7.4.3.1. Installation & Integration Services
7.4.3.2. Maintenance Service
7.5. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
7.5.1. Instruments
7.5.1.1. Quantitative Pathology Imaging System
7.5.1.2. Immunofluorescence Slide Scanner
7.5.1.3. Multispectral Imaging Systems
7.5.1.4. Toponome imaging System
7.5.2. Software
7.5.3. Services
7.5.3.1. Installation & Integration Services
7.5.3.2. Maintenance Service
7.6. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
7.6.1. Immunohistochemistry (IHC) Assay
7.6.2. Fluorescent In Situ Hybridization (FISH) Assay
7.6.3. Tissue Microarray (TMA) Assay
7.7. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
7.7.1. Immunohistochemistry (IHC) Assay
7.7.2. Fluorescent In Situ Hybridization (FISH) Assay
7.7.3. Tissue Microarray (TMA) Assay
7.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
7.8.1. Research
7.8.2. Clinical Diagnostics
7.9. Market Size (US$ Mn) Forecast, by Application, 2017-2027
7.9.1. Research
7.9.2. Clinical Diagnostics
7.10.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
7.10.1. Translational Laboratories
7.10.2. Biopharmaceutical Companies
7.10.3. Academic Institutes
7.11.Market Size (US$ Mn) Forecast, by Application, 2017-2027
7.11.1. Translational Laboratories
7.11.2. Biopharmaceutical Companies
7.11.3. Academic Institutes
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Component Type
7.12.3. By Imaging Technique
7.12.4. Application
7.12.5. End User
7.13. Key Representative Market Presence (Intensity Map)
8. Asia-Pacific Excluding Japan (APEJ) Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1. Drivers
8.2.2. Restraints
8.2.3. Trends
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
8.3.1. China
8.3.2. India
8.3.3. Australia and New Zealand
8.3.4. ASEAN
8.3.5. Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
8.4.1. China
8.4.2. India
8.4.3. Australia and New Zealand
8.4.4. ASEAN
8.4.5. Rest of APEJ
8.5. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
8.5.1. Instruments
8.5.1.1. Quantitative Pathology Imaging System
8.5.1.2. Immunofluorescence Slide Scanner
8.5.1.3. Multispectral Imaging Systems
8.5.1.4. Toponome imaging System
8.5.2. Software
8.5.3. Services
8.5.3.1. Installation & Integration Services
8.5.3.2. Maintenance Service
8.6. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
8.6.1. Instruments
8.6.1.1. Quantitative Pathology Imaging System
8.6.1.2. Immunofluorescence Slide Scanner
8.6.1.3. Multispectral Imaging Systems
8.6.1.4. Toponome imaging System
8.6.2. Software
8.6.3. Services
8.6.3.1. Installation & Integration Services
8.6.3.2. Maintenance Service
8.7. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
8.7.1. Immunohistochemistry (IHC) Assay
8.7.2. Fluorescent In Situ Hybridization (FISH) Assay
8.7.3. Tissue Microarray (TMA) Assay
8.8. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
8.8.1. Immunohistochemistry (IHC) Assay
8.8.2. Fluorescent In Situ Hybridization (FISH) Assay
8.8.3. Tissue Microarray (TMA) Assay
8.9. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
8.9.1. Research
8.9.2. Clinical Diagnostics
8.10.Market Size (US$ Mn) Forecast, by Application, 2017-2027
8.10.1. Research
8.10.2. Clinical Diagnostics
8.11.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
8.11.1. Translational Laboratories
8.11.2. Biopharmaceutical Companies
8.11.3. Academic Institutes
8.12.Market Size (US$ Mn) Forecast, by Application, 2017-2027
8.12.1. Translational Laboratories
8.12.2. Biopharmaceutical Companies
8.12.3. Academic Institutes
8.13.Drivers and Restraints: Impact Analysis
8.14. Market Attractiveness Analysis
8.14.1. By Country
8.14.2. By Component Type
8.14.3. By Imaging Technique
8.14.4. Application
8.14.5. End User
8.15. Key Representative Market Presence (Intensity Map)
9. Japan Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
9.2.1. Instruments
9.2.1.1. Quantitative Pathology Imaging System
9.2.1.2. Immunofluorescence Slide Scanner
9.2.1.3. Multispectral Imaging Systems
9.2.1.4. Toponome imaging System
9.2.2. Software
9.2.3. Services
9.2.3.1. Installation & Integration Services
9.2.3.2. Maintenance Service
9.3. Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
9.3.1. Instruments
9.3.1.1. Quantitative Pathology Imaging System
9.3.1.2. Immunofluorescence Slide Scanner
9.3.1.3. Multispectral Imaging Systems
9.3.1.4. Toponome imaging System
9.3.2. Software
9.3.3. Services
9.3.3.1. Installation & Integration Services
9.3.3.2. Maintenance Service
9.4. Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
9.4.1. Immunohistochemistry (IHC) Assay
9.4.2. Fluorescent In Situ Hybridization (FISH) Assay
9.4.3. Tissue Microarray (TMA) Assay
9.5. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
9.5.1. Immunohistochemistry (IHC) Assay
9.5.2. Fluorescent In Situ Hybridization (FISH) Assay
9.5.3. Tissue Microarray (TMA) Assay
9.6. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
9.6.1. Research
9.6.2. Clinical Diagnostics
9.7. Market Size (US$ Mn) Forecast, by Application, 2017-2027
9.7.1. Research
9.7.2. Clinical Diagnostics
9.8. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
9.8.1. Translational Laboratories
9.8.2. Biopharmaceutical Companies
9.8.3. Academic Institutes
9.9. Market Size (US$ Mn) Forecast, by Application, 2017-2027
9.9.1. Translational Laboratories
9.9.2. Biopharmaceutical Companies
9.9.3. Academic Institutes
9.10. Market Attractiveness Analysis
9.10.1. By Component Type
9.10.2. By Imaging Technique
9.10.3. Application
9.10.4. End User
9.11. Key Representative Market Presence (Intensity Map)
10. Middle East and Africa Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1. Drivers
10.2.2. Restraints
10.2.3. Trends
10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of MEA
10.4. Market Size (US$ Mn) Forecast By Country, 2017- 2027
10.4.1. GCC Countries
10.4.2. South Africa
10.4.3. Rest of MEA
10.5.Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
10.5.1. Instruments
10.5.1.1. Quantitative Pathology Imaging System
10.5.1.2. Immunofluorescence Slide Scanner
10.5.1.3. Multispectral Imaging Systems
10.5.1.4. Toponome imaging System
10.5.2. Software
10.5.3. Services
10.5.3.1. Installation & Integration Services
10.5.3.2. Maintenance Service
10.6.Market Size (US$ Mn) and Volume Forecast By Component Type, 2017-2027
10.6.1. Instruments
10.6.1.1. Quantitative Pathology Imaging System
10.6.1.2. Immunofluorescence Slide Scanner
10.6.1.3. Multispectral Imaging Systems
10.6.1.4. Toponome imaging System
10.6.2. Software
10.6.3. Services
10.6.3.1. Installation & Integration Services
10.6.3.2. Maintenance Service
10.7.Historical Market Size (US$ Mn) Analysis by Imaging Technique, 2012-2016
10.7.1. Immunohistochemistry (IHC) Assay
10.7.2. Fluorescent In Situ Hybridization (FISH) Assay
10.7.3. Tissue Microarray (TMA) Assay
10.8.Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
10.8.1. Immunohistochemistry (IHC) Assay
10.8.2. Fluorescent In Situ Hybridization (FISH) Assay
10.8.3. Tissue Microarray (TMA) Assay
10.9.Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
10.9.1. Research
10.9.2. Clinical Diagnostics
10.10. Market Size (US$ Mn) Forecast, by Application, 2017-2027
10.10.1. Research
10.10.2. Clinical Diagnostics
10.11. Historical Market Size (US$ Mn) Analysis by Application, 2012-2016
10.11.1. Translational Laboratories
10.11.2. Biopharmaceutical Companies
10.11.3. Academic Institutes
10.12. Market Size (US$ Mn) Forecast, by Application, 2017-2027
10.12.1. Translational Laboratories
10.12.2. Biopharmaceutical Companies
10.12.3. Academic Institutes
10.13. Drivers and Restraints: Impact Analysis
10.14. Market Attractiveness Analysis
10.14.1. By Country
10.14.2. By Component Type
10.14.3. By Imaging Technique
10.14.4. Application
10.14.5. End User
10.15. Key Representative Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
13.1. Competition Dashboard
13.2. Company Share Analysis
13.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments and SWOT Analysis)
13.3.1. Perkin Elmer, Inc.
13.3.2. Bio-rad Laboratories Inc.
13.3.3. Thermo Fisher Scientific, Inc.
13.3.4. Abcam plc.
13.3.5. Merck KGaA
13.3.6. Illumina Inc.
13.3.7. Leica Biosystems Nussloch GmbH
13.3.8. Ventana Medical Systems, Inc.
13.3.9. Aushon BioSystems Ltd.
13.3.10. MicroConstants, Inc.
13.3.11. ToposNomos Ltd.
14. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Region, 2012-2016
14.2.1. North America
14.2.2. Latin America
14.2.3. Western Europe
14.2.4. Eastern Europe
14.2.5. Asia Pacific Excluding Japan
14.2.6. Japan
14.2.7. Middle East and Africa
14.3. Market Size (US$ Mn) Forecast By Region, 2017-2027
14.3.1. North America
14.3.2. Latin America
14.3.3. Western Europe
14.3.4. Eastern Europe
14.3.5. Asia Pacific Excluding Japan
14.3.6. Japan
14.3.7. Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Component Type
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume Analysis By Component Type, 2012-2016
15.2.1. Instruments
15.2.1.1. Quantitative Pathology Imaging System
15.2.1.2. Immunofluorescence Slide Scanner
15.2.1.3. Multispectral Imaging Systems
15.2.1.4. Toponome imaging System
15.2.2. Software
15.2.3. Services
15.2.3.1. Installation & Integration Services
15.2.4. Maintenance Service
15.3. Market Size (US$ Mn) and Volume Forecast By Component Type,2017-2027
15.3.1. Instruments
15.3.1.1. Quantitative Pathology Imaging System
15.3.1.2. Immunofluorescence Slide Scanner
15.3.1.3. Multispectral Imaging Systems
15.3.1.4. Toponome imaging System
15.3.2. Software
15.3.3. Services
15.3.3.1. Installation & Integration Services
15.3.4. Maintenance Service
15.4. Market Attractiveness Analysis by Component Type
16. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Imaging Technique
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis, by Imaging Technique, 2012-2016
16.2.1. Immunohistochemistry (IHC) Assay
16.2.2. Fluorescent In Situ Hybridization (FISH) Assay
16.2.3. Tissue Microarray (TMA) Assay
16.3. Market Size (US$ Mn) Forecast, by Imaging Technique, 2017-2027
16.3.1. Immunohistochemistry (IHC) Assay
16.3.2. Fluorescent In Situ Hybridization (FISH) Assay
16.3.3. Tissue Microarray (TMA) Assay
16.4. Market Attractiveness Analysis by Imaging Technique
17. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By Application
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis, by Application, 2012-2016
17.2.1. Research
17.2.2. Clinical Diagnostics
17.3. Market Size (US$ Mn) Forecast, by Application, 2017-2027
17.3.1. Research
17.3.2. Clinical Diagnostics
17.4. Market Attractiveness Analysis by Application
18. Global Multiplex Biomarker Imaging Market Analysis 2012–2016 and Forecast 2017–2027, By End User
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis, by End User, 2012-2016
18.2.1. Translational Laboratories
18.2.2. Biopharmaceutical Companies
18.2.3. Academic Institutes
18.3. Market Size (US$ Mn) Forecast, by End User, 2017-2027
18.3.1. Translational Laboratories
18.3.2. Biopharmaceutical Companies
18.3.3. Academic Institutes
18.4. Market Attractiveness Analysis by End User
19. Global Market Analysis 2012–2016 and Forecast 2017–2027
19.1. Market Size and Y-o-Y Growth
19.2. Absolute $ Opportunity
20. Assumptions and Acronyms Used
21. Research Methodology
List of Tables
Table 01: CPT Codes for Digital Pathology
Table 02: DPA Regulatory FDA 510(k) List
Table 03: DPA Regulatory FDA 510(k) List
Table 04: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012–2016 and Forecast 2017–2027, By Component Type
Table 05: North America Multiplex Biomarker Imaging Market Volume Analysis 2012–2016 and Forecast 2017–2027, By Component Type
Table 06: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Imaging Technique
Table 07: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 08: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 09: North America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 10: North America Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 11: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012–2016 and Forecast 2017–2027, By Component Type
Table 12: Latin America Multiplex Biomarker Imaging Market Volume Analysis-2012–2016 and Forecast 2017–2027, By Component Type
Table 13: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Imaging Technique
Table 14: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 15: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 16: Latin America Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 17: Latin America Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 18: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012–2016 and Forecast 2017–2027, By Component Type
Table 19: Western Europe Multiplex Biomarker Imaging Market Volume Analysis-2012–2016 and Forecast 2017–2027, By Component Type
Table 20: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Imaging Technique
Table 21: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application
Table 22: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By End User
Table 23: Western Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country
Table 24: Western Europe Multiplex Biomarker Imaging Participants Presence (Intensity Mapping)
Table 25: Eastern Europe Multiplex Biomarker Imaging Market Value (US$ Mn) Analysis-2012–2016 and Forecast 2017–2027, By Component Type
Table 26: Eastern Europe M>

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report